NO20091022L - Vaksine omfattende en olje i vann emulsjons-adjuvant - Google Patents

Vaksine omfattende en olje i vann emulsjons-adjuvant

Info

Publication number
NO20091022L
NO20091022L NO20091022A NO20091022A NO20091022L NO 20091022 L NO20091022 L NO 20091022L NO 20091022 A NO20091022 A NO 20091022A NO 20091022 A NO20091022 A NO 20091022A NO 20091022 L NO20091022 L NO 20091022L
Authority
NO
Norway
Prior art keywords
oil
water emulsion
vaccine
emulsion adjuvant
composition
Prior art date
Application number
NO20091022A
Other languages
English (en)
Norwegian (no)
Inventor
Emmanuel Jules Hanon
Jr William Ripley Ballou
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en
Priority claimed from GB0620337A external-priority patent/GB0620337D0/en
Priority claimed from GB0620816A external-priority patent/GB0620816D0/en
Priority claimed from GB0620815A external-priority patent/GB0620815D0/en
Priority claimed from PCT/EP2006/069979 external-priority patent/WO2007071711A2/en
Priority claimed from GB0707697A external-priority patent/GB0707697D0/en
Priority claimed from GB0711357A external-priority patent/GB0711357D0/en
Priority claimed from GB0712062A external-priority patent/GB0712062D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20091022L publication Critical patent/NO20091022L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO20091022A 2006-10-12 2009-03-10 Vaksine omfattende en olje i vann emulsjons-adjuvant NO20091022L (no)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
PCT/EP2006/069979 WO2007071711A2 (en) 2005-12-22 2006-12-20 Vaccine
PCT/EP2006/069977 WO2007071710A2 (en) 2005-12-22 2006-12-20 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0707697A GB0707697D0 (en) 2007-04-20 2007-04-20 Vaccine
GB0711357A GB0711357D0 (en) 2007-06-12 2007-06-12 Vaccine
GB0712062A GB0712062D0 (en) 2007-06-21 2007-06-21 Vaccine
PCT/EP2007/060743 WO2008043774A1 (en) 2006-10-12 2007-10-10 Vaccine comprising an oil in water emulsion adjuvant

Publications (1)

Publication Number Publication Date
NO20091022L true NO20091022L (no) 2009-04-27

Family

ID=40551582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091022A NO20091022L (no) 2006-10-12 2009-03-10 Vaksine omfattende en olje i vann emulsjons-adjuvant

Country Status (18)

Country Link
US (2) US20100183667A1 (zh)
JP (2) JP5230632B2 (zh)
KR (1) KR101151202B1 (zh)
CN (1) CN101522218B (zh)
AU (1) AU2007306381B2 (zh)
BR (1) BRPI0717219B8 (zh)
CA (1) CA2664619C (zh)
CR (1) CR10726A (zh)
DK (1) DK2086582T3 (zh)
EA (1) EA015817B1 (zh)
ES (1) ES2397714T3 (zh)
HR (1) HRP20130023T1 (zh)
IL (1) IL197512A (zh)
MA (1) MA30866B1 (zh)
MX (1) MX2009003325A (zh)
NO (1) NO20091022L (zh)
PT (1) PT2086582E (zh)
WO (1) WO2008043774A1 (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371994C (en) * 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
EP1861122A1 (en) 2005-03-23 2007-12-05 GlaxoSmithKline Biologicals S.A. Composition
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
UA99719C2 (ru) 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
WO2009127677A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
WO2009127676A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
DK2268823T3 (da) 2008-08-28 2011-10-03 Novartis Ag Fremstilling af squalen ud fra hyperproducerende gærarter
EP2331127A2 (en) 2008-09-18 2011-06-15 Novartis AG Vaccine adjuvant combinations
EP2396030B1 (en) 2009-02-10 2015-08-12 Novartis AG Influenza vaccine regimens for pandemic-associated strains
DK2396032T3 (en) * 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010094663A1 (en) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
AU2010238255B2 (en) 2009-04-14 2014-10-16 Novartis Ag Compositions for immunising against Staphylococcus aureus
BRPI1011171A2 (pt) 2009-05-21 2015-08-25 Novartis Ag Genética reversa usando promotores poli i não-endógeno
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
PL2569267T5 (pl) 2010-05-12 2017-10-31 Novartis Ag Ulepszone sposoby otrzymywania skwalenu
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
JP2016539314A (ja) 2011-12-12 2016-12-15 ノバルティス アーゲー インフルエンザウイルス血球凝集素のためのアッセイ法
EP2793939A1 (en) 2011-12-23 2014-10-29 Novartis AG Stable compositions for immunising against staphylococcus aureus
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
DK2890394T3 (da) 2012-08-31 2019-07-15 Glaxosmithkline Biologicals Sa Stabiliserede proteiner til immunisering mod Staphylococcus aureus
JP2015528456A (ja) 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
PL2925355T3 (pl) 2012-11-30 2018-06-29 Glaxosmithkline Biologicals S.A. Antygeny pseudomonas i połączenia antygenów
JP6421128B2 (ja) 2012-12-03 2018-11-07 ノバルティス アーゲー リアソータントインフルエンザａウイルス
EP2928489B1 (en) 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
EP2976107B1 (en) * 2013-03-19 2019-02-20 ASIT BioTech s.a. Allergen preparation
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
CA2911938C (en) * 2013-05-14 2019-07-16 Zoetis Services Llc Vaccine compositions comprising sp oil and p-class immunostimulatory oligonucleotides
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
MX2015016755A (es) 2013-06-06 2016-04-13 Novartis Ag Reagrupamiento del virus de influenza.
CA2937184A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
RS59971B1 (sr) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals Sa Mutantni stafilokokni antigeni
CN106413782A (zh) * 2014-05-26 2017-02-15 贝克顿迪金森法国公司 在润滑的医用注射装置中储存乳化佐剂疫苗的方法
EP3511020B1 (en) 2014-12-02 2021-01-20 Novartis AG Manufacture of surfactant-containing compositions
CA2990745A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
BE1024160A9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
WO2018058230A1 (en) 2016-09-27 2018-04-05 Immunovaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
CN106511996B (zh) * 2016-11-04 2019-09-10 江苏省农业科学院 用于口蹄疫疫苗的复乳型佐剂及其制备方法
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
KR20210117832A (ko) * 2020-03-20 2021-09-29 강원대학교산학협력단 Gla-se를 포함하는 수족구병 백신 조성물
EP4171629A1 (en) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
JP2023538665A (ja) 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド トコフェロール含有スクアレンエマルションアジュバントを有するｃｏｖｉｄ－１９ワクチン
EP4313137A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
KR20240033309A (ko) * 2022-09-05 2024-03-12 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2905287A1 (de) 1979-02-12 1980-08-21 Siemens Ag Verfahren zur automatischen elektrochemischen endpunktsbestimmung einer titration
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4454119A (en) 1981-06-29 1984-06-12 Mitsubishi Chemical Industries Limited Therapeutic agents
FI69639C (fi) * 1982-07-02 1986-03-10 Orion Yhtymae Oy Preparat foer anvaendning vid klamydia-diagnostik
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ES2160570T3 (es) 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ES2109921T3 (es) 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
WO1993010152A1 (en) 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
EP0812358A1 (en) 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
EP0914178B1 (en) 1996-06-18 2003-03-12 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US20030133944A1 (en) * 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998028037A1 (en) 1996-12-20 1998-07-02 Alza Corporation Device and method for enhancing transdermal agent flux
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
CN1285753A (zh) 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
JP2001316251A (ja) * 2000-02-24 2001-11-13 Fuairudo Kk 炭素燃焼残査の超微粒子を含むスクワラン及びその製造方法
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
PT1719511E (pt) 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
EP1861122A1 (en) * 2005-03-23 2007-12-05 GlaxoSmithKline Biologicals S.A. Composition
EP2377552A3 (en) * 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
AR066405A1 (es) * 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna

Also Published As

Publication number Publication date
EA015817B1 (ru) 2011-12-30
AU2007306381A1 (en) 2008-04-17
IL197512A (en) 2013-10-31
PT2086582E (pt) 2013-01-25
BRPI0717219B8 (pt) 2021-05-25
MX2009003325A (es) 2009-04-09
ES2397714T3 (es) 2013-03-08
US9700605B2 (en) 2017-07-11
CN101522218A (zh) 2009-09-02
US20100183667A1 (en) 2010-07-22
IL197512A0 (en) 2011-08-01
US20150359863A1 (en) 2015-12-17
HRP20130023T1 (hr) 2013-02-28
JP5230632B2 (ja) 2013-07-10
JP2013067646A (ja) 2013-04-18
CN101522218B (zh) 2012-09-26
CA2664619C (en) 2012-12-11
JP2010505907A (ja) 2010-02-25
JP5767201B2 (ja) 2015-08-19
BRPI0717219B1 (pt) 2021-01-19
BRPI0717219A2 (pt) 2015-05-26
DK2086582T3 (da) 2013-02-04
EA200900350A1 (ru) 2009-10-30
KR20090066323A (ko) 2009-06-23
CA2664619A1 (en) 2008-04-17
WO2008043774A1 (en) 2008-04-17
MA30866B1 (fr) 2009-11-02
AU2007306381B2 (en) 2011-12-08
KR101151202B1 (ko) 2012-06-11
CR10726A (es) 2009-05-25

Similar Documents

Publication Publication Date Title
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
CY1116904T1 (el) Εμβολιο
EP2455101A3 (en) Influenza vaccine with oil-in-water emulsion adjuvant
ES2585810T3 (es) Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
NO20065039L (no) Mikrofluidisert olje i vann emulsjon og vaksinesammensetninger
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
EA200900024A1 (ru) Противогриппозная вакцина
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
TW200716165A (en) Novel vaccine formulations
EA201001478A1 (ru) Вакцина
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
EP2377551A3 (en) Adjuvanted influenza vaccines including cytokine-inducing agents
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
UA95646C2 (ru) Вакцина, которая включает адъювант на основе эмульсии масло-в-воде
DOP2009000068A (es) Vacuna que comprende un adyuvante de emulsión de aceite en agua
MX2009010963A (es) Vacuna de influenza de emulsion de aceite en agua.
UA91701C2 (ru) Мультивалентная иммуногенная композиция против гриппа, которая включает антиген вируса гриппа и адъювант на основе эмульсии масла-в-воде
AR111910A2 (es) Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos
SG139618A1 (en) Influenza vaccine
SG160386A1 (en) Novel composition
TH72570B (th) อิมัลชันของน้ำมันในน้ำชนิดผ่านการไมโครฟลูอิดไดซ์ และองค์ประกอบของวัคซีน
WO2005072679A3 (es) Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application